I meant from purchasing from a generic manufacturer or India if they were available there.
I wasn’t aware of this graph. How reliable is it, and what about in the most recent years? Just curious.
Manufacturing costs might also differ depending on the mAb.
Open access paper: https://www.mayoclinicproceedings.org/article/S0025-6196(20)30985-X/fulltext
Objective: To resolve the historical inconsistency regarding the cardiovascular benefits of Omega-3 fatty acids (EPA and DHA) by conducting a meta-analysis that specifically evaluates the relationship between dosage and cardiovascular outcomes.
Methods: The authors performed a systematic review and meta-regression of **40 randomized controlled trials (RCTs)**involving a combined total of 135,267 participants. They analyzed the effects of EPA and DHA supplementation on myocardial infarction (MI), coronary heart disease (CHD) events, CVD events, and mortality.
Key Findings:
Full analysis here: https://gemini.google.com/share/38109d243b8f
I’m more impressed by this study:
Conclusion
Findings underscore associations of midlife Mediterranean-style diet and lower presence of subclinical carotid atherosclerosis at Age 60 and confirm the significance of dietary interventions as potential means for cardiovascular disease prevention. The study enhances understanding of long-term dietary patterns and their link to subclinical atherosclerosis, supporting future interventions and further research.
Open Paper: https://academic.oup.com/eurjpc/article/32/16/1614/8084907?login=false
I believe so. Whenever I’ve taken it, I have noticed zero side effects (besides dark stools) and it reliably increased my ferritin quickly. It can be taken with or without food and still be well absorbed.
I think a good sleep mask is critical. I wear one every night and bring it on every trip I go on.
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality worldwide, and LDL-cholesterol (LDL-C) plays a fundamental causal role. The classic INTERHEART study showed that dyslipidemia, characterized by an elevated apolipoprotein B/apolipoprotein AI ratio, was the risk factor with the highest population-attributable risk (PAR) for myocardial infarction (MI) (PAR 49.2% for the top four quintiles vs. the lowest quintile).
Despite strong evidence supporting the benefits of statins in reducing ASCVD, misinformation about this therapy continues to spread widely on social media, potentially increasing the risk of clinical events for the population. A Danish study showed that early statin discontinuation was more common after exposure to negative media coverage and was linked to a higher risk of MI and ASCVD death. Misinformation is a threat that needs to be fought because it causes delays in starting lipid-lowering treatment, denying many patients its benefits.
LDL-cholesterol lowering, the earlier the better: lessons from the real world
Aortic stenosis is one of the most common and deadly forms of heart valve disease, affecting millions worldwide. The condition develops gradually as the aortic valve narrows, eventually limiting blood flow from the heart. Yet despite its prevalence, medicine still lacks drugs that can prevent or slow its progression. Once the disease becomes severe, patients are left with only one option: valve replacement through surgery or catheter-based procedures.
A new study from researchers at UC San Francisco and the Broad Institute of MIT and Harvard suggests that this reactive approach may not be inevitable. By combining artificial intelligence–based imaging analysis with large-scale human genetics, the team has uncovered early genetic signals that shape aortic valve function long before clinical disease develops. The findings, published in Nature Genetics, point toward a future in which aortic stenosis could be detected, and potentially intercepted, years earlier.